All Pharma News
Novo Licenses to Almirall Potential First-in-Class Antibody Candidate

Novo Licenses to Almirall Potential First-in-Class Antibody Candidate
BIOSPACE
20 Feb 2024
Share Share
Almirall continues its progress to leadership in Medical Dermatology

Almirall continues its progress to leadership in Medical Dermatology
BUSINESSWIRE
19 Feb 2024
Share Share
Almirall Initiates First Phase I Clinical Study of ALM223

Almirall Initiates First Phase I Clinical Study of ALM223
BUSINESSWIRE
21 Dec 2023
Share Share
Almirall partners with etherna

Almirall partners with etherna
Katherine ENDPTS
12 Dec 2023
Share Share
Almirall`s Ebglyss (Lebrikizumab) Receives Approval in Europe

Almirall`s Ebglyss (Lebrikizumab) Receives Approval in Europe
EMA
24 Nov 2023
Share Share
Almirall Receives European Commission Approval of EBGLYSS

Almirall Receives European Commission Approval of EBGLYSS
BUSINESSWIRE
17 Nov 2023
Share Share
Almirall and Absci announce AI drug discovery partnership

Almirall and Absci announce AI drug discovery partnership
BUSINESSWIRE
14 Nov 2023
Share Share
Almirall’s Nine-month 2023 Results:

Almirall’s Nine-month 2023 Results:
BUSINESSWIRE
09 Nov 2023
Share Share
Almirall: 80% of patients with atopic dermatitis maintained clear skin with lebrikizumab

Almirall: 80% of patients with atopic dermatitis maintained clear skin with lebrikizumab
BUSINESSWIRE
20 Oct 2023
Share Share
Almirall`s Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe AD

Almirall`s Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe AD
BUSINESSWIRE
13 Oct 2023
Share Share